HomeBlog of Signaling Pathways

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Blog of Signaling Pathways

Factors contributing to the utilization of robotic colorectal surgery: a systematic review and meta-analysis

58 views | Dec 17 2022

Dana M Hayden et al. identifies nonclinical disparities in access to robotics that should be addressed to provide more equitable access to innovations in colorectal surgery. [Read the Full Post]

BL-918, a small-molecule activator of ULK1, induces cytoprotective autophagy for amyotrophic lateral sclerosis therapy

36 views | Dec 17 2022

Wei Liu et al. found that ULK1 activator BL-918 displayed a therapeutic potential on ALS through inducing cytoprotective autophagy. [Read the Full Post]

Rational Design and Synthesis of D-galactosyl Lysophospholipids as Selective Substrates and non-ATP-competitive Inhibitors of Phosphatidylinositol Phosphate Kinases

58 views | Dec 16 2022

Mengxia Sun et al. thought that D-galactose-based phosphoinositide mimetics could be developed into artificial substrates and new inhibitors of PIPKs. [Read the Full Post]

3-deazaadenosine (3DA) alleviates senescence to promote cellular fitness and cell therapy efficiency in mice

49 views | Dec 16 2022

Ana Guerrero et al. identified 3DA as a promising drug enhancing the efficiency of cellular therapies by restraining senescence. [Read the Full Post]

APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice

159 views | Dec 15 2022

Eun Soo Lee et al. suggested that APX-115 might be a promising therapeutic agent for the treatment of DN because of its pan-NOX inhibitory activity, including its NOX5 inhibitory activity, and also owing to its anti-inflammatory effect. [Read the Full Post]

Apilimod enhances specific productivity in recombinant CHO cells through cell cycle arrest and mediation of autophagy

56 views | Dec 15 2022

Jiang-Tao Lu et al. found the potential of apilimod for development as a novel enhancer for the production of recombinant proteins in CHO cell engineering. [Read the Full Post]

Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells

117 views | Dec 14 2022

Wioleta Dudka et al. proposed that personalized treatment based on the genetic selection of patients carrying mutations that caused overactivation of the targeted pathways. [Read the Full Post]

Recent updates on Wnt signaling modulators: a patent review (2014-2020)

49 views | Dec 14 2022

Vishalgiri G Goswami et al. thought that targeting Wnt pathway could be a potential approach to design and develop novel therapeutic classes. [Read the Full Post]

The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target

94 views | Dec 13 2022

Martina Mazzariol et al. found that avacopan, a C5aR inhibitor, showed beneficial effects in AAV and representd a promising therapy to achieve sustained remission and to spare glucocorticoids. [Read the Full Post]

Identification of potential drug targets for vascular dementia and carotid plaques by analyzing underlying molecular signatures shared by them

86 views | Dec 13 2022

Jun Shu et al.found that inflammatory and immune-related processes be a crucial common pathophysiological mechanism shared by VaD and carotid plaques. [Read the Full Post]

Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease

87 views | Dec 12 2022

Fredrik R Zetterberg et al. found a high affinity (nM) thiodigalactoside GB0139 which was in clinical development (PhIIb) as an inhaled treatment of idiopathic pulmonary fibrosis. [Read the Full Post]

Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells

36 views | Dec 12 2022

Tung-Sun Huang et al. thought that lenvatinib and selumetinib decreased SREBP1 expression in the BRAF-mutant cell line BHT-101. [Read the Full Post]

MAT2A as Key Regulator and Therapeutic Target in MLL r Leukemogenesis

41 views | Dec 11 2022

Kathy-Ann Secker et al. uncovered MAT2A as a key regulator in MLL leukemogenesis and its inhibition led to significant anti-leukemic effects. [Read the Full Post]

Fifty Shades of Scandium: Comparative Study of PET Capabilities Using Sc-43 and Sc-44 with Respect to Conventional Clinical Radionuclides

86 views | Dec 11 2022

Thiago V M Lima et al. thought that accurate quantitative scandium-43/44 PET/CT was achievable in commercial devices. [Read the Full Post]

Novel biallelic mutations in TTC29 cause asthenoteratospermia and male infertility

64 views | Dec 10 2022

Siyu Dai et al. found the novel biallelic mutations in TTC29 in a MMAF patient, which findings expand the mutational spectrum of TTC29. [Read the Full Post]

Unearthing the Janus-face cholesterogenesis pathways in cancer

41 views | Dec 10 2022

Babita Madan et al. suggested a potential role of disrupted cholesterol biosynthesis, in coordination with imported cholesterol, as a factor in cancer development. [Read the Full Post]

Asthma-related inflammation promotes lung metastasis of breast cancer cells through CCL11-CCR3 pathway

38 views | Dec 09 2022

S Bekaert et al. thought that asthma related inflammation in lungs might be a risk factor for lung metastasis in breast cancer patients. [Read the Full Post]

Inhibition of ACLY Leads to Suppression of Osteoclast Differentiation and Function Via Regulation of Histone Acetylation

46 views | Dec 09 2022

Qian Guo et al. proved that inhibition of ATP-citrate lyase led to suppression of osteoclast differentiation and function via regulation of histone acetylation. [Read the Full Post]

Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion

51 views | Dec 08 2022

Michael H Storandt et al. found that FGFR inhibitors, including pemigatinib, had shown promise in the management of CCA with FGFR2 fusion or rearrangement. [Read the Full Post]

The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy

63 views | Dec 08 2022

Taotao Li et al. thought that the TKIs might become an 8p11 treatment option as an alternative to hematopoietic stem cell transplantation. [Read the Full Post]